Clarkston Capital Partners LLC Has $22.24 Million Stock Position in IQVIA Holdings Inc. $IQV

Clarkston Capital Partners LLC reduced its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 48.4% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 130,423 shares of the medical research company’s stock after selling 122,102 shares during the quarter. IQVIA comprises 1.7% of Clarkston Capital Partners LLC’s holdings, making the stock its 22nd largest holding. Clarkston Capital Partners LLC’s holdings in IQVIA were worth $22,242,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of IQV. Ameliora Wealth Management Ltd. acquired a new stake in shares of IQVIA during the 4th quarter worth approximately $25,000. International Assets Investment Management LLC acquired a new position in shares of IQVIA during the 4th quarter valued at $27,000. Gilpin Wealth Management LLC bought a new position in IQVIA during the fourth quarter worth $27,000. CrossGen Wealth LLC acquired a new stake in IQVIA in the fourth quarter worth $28,000. Finally, Activest Wealth Management grew its holdings in IQVIA by 590.0% in the fourth quarter. Activest Wealth Management now owns 138 shares of the medical research company’s stock worth $31,000 after purchasing an additional 118 shares during the period. 89.62% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

IQV has been the topic of several research reports. Weiss Ratings upgraded shares of IQVIA from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday, July 15th. HSBC reaffirmed a “buy” rating and issued a $240.00 target price on shares of IQVIA in a research report on Monday, July 6th. Wall Street Zen lowered IQVIA from a “buy” rating to a “hold” rating in a report on Saturday, June 27th. Evercore reissued an “outperform” rating and issued a $185.00 price objective on shares of IQVIA in a research note on Wednesday, April 8th. Finally, Robert W. Baird boosted their price objective on IQVIA from $230.00 to $249.00 and gave the company an “outperform” rating in a report on Wednesday, July 1st. Thirteen analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat, IQVIA presently has an average rating of “Moderate Buy” and an average price target of $225.71.

IQVIA Stock Performance

Shares of IQVIA stock opened at $207.06 on Friday. IQVIA Holdings Inc. has a 52 week low of $154.50 and a 52 week high of $247.04. The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 2.20. The business has a 50 day moving average price of $187.45 and a 200-day moving average price of $187.23. The company has a market cap of $34.56 billion, a PE ratio of 25.66, a price-to-earnings-growth ratio of 1.78 and a beta of 1.20.

IQVIA (NYSE:IQV) last announced its earnings results on Tuesday, May 5th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.83 by $0.07. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.The company had revenue of $4.15 billion for the quarter, compared to analysts’ expectations of $4.10 billion. During the same quarter in the previous year, the firm earned $2.70 earnings per share. IQVIA’s quarterly revenue was up 8.4% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. Equities analysts anticipate that IQVIA Holdings Inc. will post 11.57 earnings per share for the current fiscal year.

IQVIA announced that its Board of Directors has approved a stock buyback plan on Thursday, May 7th that permits the company to repurchase $2.00 billion in shares. This repurchase authorization permits the medical research company to buy up to 6.8% of its stock through open market purchases. Stock repurchase plans are usually an indication that the company’s board of directors believes its stock is undervalued.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.